SEC Form 4 research

Hemab Therapeutics Holdings, Inc. insider transactions

Inspect Hemab Therapeutics Holdings, Inc.'s public SEC insider acquisitions and sales, reporting owners and source receipts.

As of 2026-10-07T00:29:11.873Z

Issuer CIK
0002114044
Reporting owners
21
Officers and directors
2

Recent insider disclosures

This table includes purchases, sales and awards in the public filing record. Awards and open-market purchases are distinct transaction codes. For historical research, use the public availability date to determine when the transaction was knowable.

Read code P as a purchase, S as a sale and A as an award. An award is an acquisition, but it is not an open-market purchase. Open the filing receipt to check the transaction details.

2026-09-252026-09-24Walbert KeliA36,000$0Not reported

Most recent 90-day source activity, up to 50 rows. No rows means no matching recent records, not no historical activity.

Officers and directors in the directory

RA Capital Nexus Fund II, L.P.000182537686
Kolchinsky Peter00013848591,065
RA Capital Healthcare Fund LP00013150821,037
RA CAPITAL MANAGEMENT, L.P.00013468241,063
RA Capital Nexus Fund IV, L.P.00020535866
Shah Rajeev M.0001619841370

Which transactions qualify for the company tracker

The company strategy uses verified officers and directors with qualifying acquisitions at this issuer. Other reporting owners may appear in source records without becoming strategy signals.

Strategy eligibility is held while filing coverage is unresolved.

Historical follower simulations are separate from these source transactions. They do not establish live trading results.